Vertex and Eli Lilly are revolutionizing non-opioid pain management with NaV1.8 advancements. See why I'm bullish about LLY ...

Asad Haider, head of the healthcare business unit within Goldman Sachs Research, now forecasts the market for anti-obesity drugs, particularly those using injectable versions of GLP 1-based drugs, to ...

Analyst Evan Seigerman reaffirmed his strong outlook for LLY stock after the U.S. pharmaceutical giant announced its plans to acquire privately held SiteOne Therapeutics for $1 billion in a deal that ...

Eli Lilly and Company and SiteOne Therapeutics, Inc., a private biotechnology company developing small molecule inhibitors of ...

About SiteOne Landscape Supply SiteOne supplies irrigation, lighting, landscape supplies, fertilizers, turf protection products, grass seed, turf care equipment and more. SiteOne Landscape Supply is ...

Eli Lilly’s acquisition of SiteOne Therapeutics comes ahead of Phase 2 testing of the startup’s lead drug candidate, which ...

Pharmaceutical company Eli Lilly has announced plans to acquire private biotech company SiteOne in a deal worth up to $1 ...

Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines ...

Discover the latest business headlines, including Ross raising prices, United Airlines' new check-in requirements, and Hefty's 60th birthday celebration.

US pharma major Eli Lilly (NYSE: LLY) has announced a definitive agreement to acquire SiteOne Therapeutics, a private ...